Nephrogen
YC S20Techstars '25New York City, US · Founded 2022 · 5 employees · 3 known investors
Nephrogen develops AI-powered AAV delivery vehicles for genetic medicines targeting kidney and pancreatic diseases. The company uses high-throughput in vivo screening to design tissue-specific viral vectors that are significantly more efficient and less immunogenic than existing alternatives.
AI & Machine LearningBiotechData & InfrastructureHealthtechMedical DevicesGene TherapyCRISPRUnited States of AmericaAmerica / Canada
Founders & leadership· Y Combinator alumni (S20)
Nephrogen was founded in 2022 by Demetri Maxim.
DM
Demetri MaximFounder and CEO
VB
Vivek BhallaChief Medical Officer
Investors · 3
Competitors · 4
by search overlap
Biogen Idec28 shared keywordsBiogen is a biotechnology company founded in 1978 that focuses on breakthroughs in biology. The company serves patients through research and development in the life sciences industry.
Bioworld26 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
PepGen14 shared keywordsPepGen is a clinical-stage biotech company developing oligonucleotide therapies for neuromuscular and neurological diseases using its Enhanced Delivery Oligonucleotide (EDO) platform to improve tissue penetration and uptake in muscle tissues.
Precigen13 shared keywordsPrecigen is a biopharmaceutical company developing gene and cell therapies, including PAPZIMEOS (zopapogene imadenovec-drba), an FDA-approved immunotherapy for adults with recurrent respiratory papillomatosis. The company focuses on immuno-oncology and immunotherapy treatments delivered via subcutaneous injection.
Companies competing with Nephrogen for the same Google search keywords, organic and paid, via search-intersection analysis.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2023 | $325K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Nephrogen do?
- Nephrogen develops AI-powered AAV delivery vehicles for genetic medicines targeting kidney and pancreatic diseases. The company uses high-throughput in vivo screening to design tissue-specific viral vectors that are significantly more efficient and less immunogenic than existing alternatives.
- Who founded Nephrogen?
- Nephrogen was founded by Demetri Maxim in 2022.
- Who are Nephrogen's investors?
- Nephrogen's investors include Techstars, Y Combinator, ZAKA VC.
- Where is Nephrogen headquartered?
- Nephrogen is headquartered in New York City, US.